Presenting our data in Ewing sarcoma at #ASCO24 Elite work by Maysa Vilbert Jonathan N. Priantti Meta-analysis evaluating second line TKIs in Ewing Sarcoma Meta Analysis Academy UVA

Excited to see our #MetaMasters and Experts shining at the ASCO 2024 conference in Chicago. Amazing work team! #ASCO2024 #MedTwitter #OncoDaily

Please come and visit our poster n506 « Efficacy of Osimertinib in uncommon EGFR mutations” review and meta-analysis Jonathan N. Priantti will there to charmingly answer all your questions. Honored to be a co-authors Jair Bar Alessio Cortellini Rafeh Naqash, MD, FASCO #ASCO24

Pooled analysis of TKI for advanced Ewing Sarcoma. Thanks for the wonderful support and mentorship Ludimila Cavalcante 😃!

Just released! Our meta-analysis underscores the importance of increasing awareness about lorlatinib-related neurocognitive adverse events (NAEs) to improve their recognition and reporting, thereby enhancing NSCLC patients' quality of life. Link: mdpi.com/2072-6694/16/1…

It was really fun to be a part of this collaborative work putting a lot of data on the efficacy of osi on rare EGFR NSCLC. Special kudos to Jonathan N. Priantti who made a huge effort on this project as well as superb supervision by Maysa Vilbert and Rafeh Naqash, MD, FASCO and many others!

✨Our publication in JCOPO on the efficacy of osimertinib in rare EGFR NSCLC is out! Grateful to collaborate with such a talented team to improve patient care! Jonathan N. Priantti, Yu Fujiwara, MD, Alessio Cortellini, Ludimila Cavalcante and many others! Thank you for the mentorship of Rafeh Naqash, MD, FASCO! 👏

✨Our publication in JCOPO on the efficacy of osimertinib in rare EGFR NSCLC is out! Grateful to collaborate with such a talented team to improve patient care! Jonathan N. Priantti,Yu Fujiwara, MD,Alessio Cortellini, Ludimila Cavalcante and many others! Thank you for the mentorship of Rafeh Naqash, MD! 👏😃

So proud to share our work in JCO Precision Oncology 🫁Our meta-analysis highlights the safety and efficacy of #osimertinib in patients with #NSCLC and uncommon #EGFR mutations. I’m really glad and honored to have this amazing international collaboration with this dream team.

This paper is part of our Collection: Antibody-drug conjugates in breast oncology Submit your research by April 9, 2025! 🔗 journals.sagepub.com/topic/collecti… Thanks Isabella Michelon, Maysa Silveira Vilbert, Jonathan N. Priantti, Ludimila Cavalcante, Evandro de Azambuja, MD, PhD, Paolo Tarantino & team!

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/39574495/ ✍️Maysa Vilbert Paolo Tarantino Evandro de Azambuja, MD, PhD Ludimila Cavalcante #ADCs #HER2low